Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease - Full Text View

Purpose

Sickle cell disease (SCD) is the most common inherited disease of the world affecting African and Caribbean populations. SCD is caused by the homozygous inheritance of the gene for sickle hemoglobin (HbS). Most patients with SCD develop abnormal pulmonary function characterized by airway obstruction, restrictive lung disease, abnormal diffusing capacity, hypoxemia and pulmonary hypertension In healthy subjects, lung capillary blood volume (Qc) and membrane diffusing capacity (Dm) can be accurately measured by the nitric oxide-carbon monoxide (NO-CO) method. We propose to study, for the first time, lung capillary blood volume and alveolar membrane diffusing capacity, using the NO-CO method, in children with SCD aged of at least 6 years Early determination of lung function and pulmonary circulation in children with SCD is very important, not only for the understanding of physiopathologic mechanisms of the disease but also for a better therapeutic management of these children.

Condition	Intervention	Phase
Sickle Cell Disease	Other: NO-CO inhalation and expiration	Phase III

Genetics Home Reference related topics:

sickle cell disease

MedlinePlus related topics:

Sickle Cell Anemia

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Active Control, Parallel Assignment

Official Title:	Evaluation of the Lung Capillary Blood Volume in Children With Sickle Cell Disease

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:

Study of lung capillary blood volume and alveolar membrane diffusing capacity using NO-CO method [ Time Frame: The day of the measure ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Respiratory physiopathology's study in sickle cell disease [ Time Frame: At the induction of the study ] [ Designated as safety issue: Yes ]
Valid alveolar membrane diffusing capacity using NO-CO in children with or without sickle cell disease [ Time Frame: At the induction of the study ] [ Designated as safety issue: Yes ]
Purpose respiratory function follow up in sickle cell disease child [ Time Frame: At the induction of the study ] [ Designated as safety issue: Yes ]
Find relationship between these vascular abnormalities and NO metabolism [ Time Frame: At the induction of the study ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	240
Study Start Date:	February 2008
Estimated Study Completion Date:	December 2009
Estimated Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Children with sickle cell disease	Other: NO-CO inhalation and expiration NO-CO inhalation and expiration
2: Active Comparator Healthy volunteers	Other: NO-CO inhalation and expiration NO-CO inhalation and expiration

Detailed Description:

We propose to study, for the first time, lung capillary blood volume and alveolar membrane diffusing capacity, using the NO-CO method, in children with SCD aged of at least 6 years. We will compare lung function and measurement of Qc and Dm in 2 groups of 120 subjects, one group of SCD children, and the other of normal children matched on age and ethnic origin. Measurement of lung capillary blood will be measured twice, to assess short term reproducibility. The measurement will be done in sitting position and lying down for one part of subjects, and at rest and during a moderate rectangular exercise for the other part of subjects. These different tests are designed to assess the physiological adaptation of pulmonary circulation in these two populations of children. Combined with complete lung function measurements, echocardiographic assessment of pulmonary hemodynamics, and measurement of exhaled nitric oxide, these evaluations will lead to a better understanding of pathophysiology of lung injury in SCD. The study will be completes at Robert Debré Hospital, in close collaboration with Sickle Cell Disease Center and Physiology Department. Children will be included after informed consent signed, as legally prescribed.

Eligibility

Ages Eligible for Study:	6 Years to 18 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Children between 6 and 18 years
Sickle cell disease( SS,SC, SBETA O, SDpunjab) and control without sickle cell disease
Social insurance
Signed informed consent

Exclusion Criteria:

Respiratory disease other tha asthma
Cardiac disease
Encephalopathy
G6PD deficiency
Consent not signed

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00560261

Contacts


Contact: Florence MISSUD, Md	01 40 03 23 52	florence.missud@rdb.aphp.fr

Locations


France
	Hopital Robert DEBRE	Recruiting
	Paris, France, 75019
	Contact: Florence MISSUD, Md 01 40 03 23 52 florence.missud@rdb.aphp.fr
	Contact: Florence MISSUD, Md 01 40 03 23 52 florence.missud@rdb.aphp.fr
	Principal Investigator: Florence MISSUD, Md

Sponsors and Collaborators

Assistance Publique - Hôpitaux de Paris

Investigators


Principal Investigator:	Florence MISSUD, Md	Assistance Publique - Hôpitaux de Paris

More Information

Responsible Party:	Department Clinical Research of Developpement ( Amel Ouslimani )
Study ID Numbers:	P061013, ID-RCB-2007-A00913-50
First Received:	November 16, 2007
Last Updated:	March 26, 2008
ClinicalTrials.gov Identifier:	NCT00560261
Health Authority:	France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:

Sickle cell disease;

Lung capillary blood volume;

Children

Study placed in the following topic categories:

Anemia, Hemolytic, Congenital

Genetic Diseases, Inborn

Hematologic Diseases

Hemoglobinopathies

Anemia

Anemia, Hemolytic

Hemoglobinopathy

Anemia, Sickle Cell

Sickle cell anemia

ClinicalTrials.gov processed this record on December 03, 2008

Sponsored by:	Assistance Publique - Hôpitaux de Paris
Information provided by:	Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:	NCT00560261